Psychedelic science in post-COVID-19 psychiatry
John R. Kelly, Matthew Crockett, Laith Alexander, Martin Haran, Amanda W Baker, Lisa M. Burke, Christine Brennan, Veronica O’keane
Irish Journal of Psychological Medicine August 19, 2020 DOI: 10.1017/ipm.2020.94 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Double-blind Peer reviewed |
|---|---|
| Intervention | Psilocybin therapy |
| Topics | Depression Psilocybin |
| Keywords | Hallucinogen Mental health Psychotherapist Cognition |
| Citations | 16 |
| Key findings | Psilocybin therapy offers a promising transdiagnostic treatment strategy for disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. |
Abstract
The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry.